Literature DB >> 23788255

What do we currently know about metabolic syndrome and atrial fibrillation?

Marijana Tadic1, Branislava Ivanovic, Cesare Cuspidi.   

Abstract

Metabolic syndrome represents a cluster of atherogenic risk factors including hypertension, insulin resistance, obesity, and dyslipidemia. Considering that all of these risk factors could influence the development of atrial fibrillation, an association between atrial fibrillation and the metabolic syndrome has been suggested. Additionally, oxidative stress and inflammation have been involved in the pathogenesis of both metabolic syndrome and atrial fibrillation. The mechanisms that relate metabolic syndrome to the increased risk of atrial fibrillation occurrence are not completely understood. Metabolic syndrome and atrial fibrillation are associated with increased cardiovascular morbidity and mortality. Because atrial fibrillation is the most common arrhythmia, and along with the prevalence of metabolic syndrome constantly increasing, it would be very important to determine the relationship between these 2 entities, especially due to the fact that the risk factors of metabolic syndrome are mainly correctable. This review focused on the available evidence supporting the association between metabolic syndrome components and metabolic syndrome as a clinical entity with atrial fibrillation.
© 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23788255      PMCID: PMC6649365          DOI: 10.1002/clc.22163

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  10 in total

1.  Evaluation of the Association Between Retinal Vein Occlusion and the Risk of Atrial Fibrillation Development: A 12-Year, Retrospective Nationwide Cohort Study.

Authors:  Tyler Hyungtaek Rim; Jaewon Oh; Christopher Seungkyu Lee; Sung Chul Lee; Seok-Min Kang; Sung Soo Kim
Journal:  Sci Rep       Date:  2016-11-07       Impact factor: 4.379

Review 2.  Linking atrial fibrillation with non-alcoholic fatty liver disease: potential common therapeutic targets.

Authors:  Ya-Hui Ding; Yuan Ma; Lin-Yan Qian; Qiang Xu; Li-Hong Wang; Dong-Sheng Huang; Hai Zou
Journal:  Oncotarget       Date:  2017-07-24

3.  Assessment of atrial electromechanical interval and P wave dispersion in patients with polycystic ovary syndrome.

Authors:  Pınar Türker Bayır; Ümit Güray; Serkan Duyuler; Burcu Demirkan; Oya Kayaalp; Selçuk Kanat; Yeşim Güray
Journal:  Anatol J Cardiol       Date:  2015-03-23       Impact factor: 1.596

4.  Monotherapy of experimental metabolic syndrome: II. Study of cardiovascular effects.

Authors:  Vladimír Knezl; Ružena Sotníková; Zuzana Brnoliaková; Tatiana Stankovičová; Viktor Bauer; Štefan Bezek
Journal:  Interdiscip Toxicol       Date:  2018-02-14

5.  Risk prediction for new-onset atrial fibrillation using the Minnesota code electrocardiography classification system.

Authors:  Yu Igarashi; Kotaro Nochioka; Yasuhiko Sakata; Tokiwa Tamai; Shinya Ohkouchi; Toshiya Irokawa; Hiromasa Ogawa; Hideka Hayashi; Takahide Fujihashi; Shinsuke Yamanaka; Takashi Shiroto; Satoshi Miyata; Jun Hata; Shogo Yamada; Toshiharu Ninomiya; Satoshi Yasuda; Hajime Kurosawa; Hiroaki Shimokawa
Journal:  Int J Cardiol Heart Vasc       Date:  2021-03-31

6.  Genomic and Proteomic Study of the Inflammatory Pathway in Patients With Atrial Fibrillation and Cardiometabolic Syndrome.

Authors:  Hana A Itani; Miran A Jaffa; Joseph Elias; Mohammad Sabra; Patrick Zakka; Jad Ballout; Amira Bekdash; Rand Ibrahim; Moustafa Al Hariri; Mirna Ghemrawi; Bernard Abi-Saleh; Maurice Khoury; Samir Alam; Rami Mahfouz; Ayad A Jaffa; Sami T Azar; Marwan M Refaat
Journal:  Front Cardiovasc Med       Date:  2020-12-02

7.  The association between insulin resistance and atrial fibrillation: A cross-sectional analysis from SPRINT (Systolic Blood Pressure Intervention Trial).

Authors:  Monique E Cho; Timothy E Craven; Alfred K Cheung; Stephen P Glasser; Mahboob Rahman; Elsayed Z Soliman; Randall S Stafford; Karen C Johnson; Jeffrey T Bates; Anna Burgner; Addison A Taylor; Leonardo Tamariz; Rocky Tang; Srinivasan Beddhu
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-09-03       Impact factor: 3.738

8.  Trajectories of Cardiovascular Risk Factors and Incidence of Atrial Fibrillation Over a 25-Year Follow-Up: The ARIC Study (Atherosclerosis Risk in Communities).

Authors:  Faye L Norby; Elsayed Z Soliman; Lin Y Chen; Lindsay G S Bengtson; Laura R Loehr; Sunil K Agarwal; Alvaro Alonso
Journal:  Circulation       Date:  2016-08-23       Impact factor: 29.690

9.  Electrocardiographic data should be coupled with tissue-Doppler imaging and clinical follow-up evaluation to determine cardiac involvement in lichen planus.

Authors:  Uğur Canpolat; Osman Turak; Fırat Özcan; Dursun Aras; Sinan Aydoğdu
Journal:  Clinics (Sao Paulo)       Date:  2013-10       Impact factor: 2.365

10.  VLDL from Metabolic Syndrome Individuals Enhanced Lipid Accumulation in Atria with Association of Susceptibility to Atrial Fibrillation.

Authors:  Hsiang-Chun Lee; Hsin-Ting Lin; Liang-Yin Ke; Chi Wei; Yi-Lin Hsiao; Chih-Sheng Chu; Wen-Ter Lai; Shyi-Jang Shin; Chu-Huang Chen; Sheng-Hsiung Sheu; Bin-Nan Wu
Journal:  Int J Mol Sci       Date:  2016-01-20       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.